The S&P/ASX 300 Index (ASX: XKO) is pushing higher today, following a rebound after Monday's heavy loss.
During mid-afternoon trade, the ASX 300 is up 1.21% to 7,386.5 points.
Let's take a look at which ASX companies are making headlines today.
News Corp (ASX: NWS)
The News Corp share price is topping the charts, up 7.86% to $32.39 during afternoon trade.
With no news coming out of the media company, it appears investors are in agreeance with Goldman Sachs' latest appraisal.
The multinational investment broker reaffirmed its "buy" rating with a 12-month price target of $44.50 on its shares.
Novonix Ltd (ASX: NVX)
The Novonix share price is storming 7.63% to another all-time high of $6.49.
The company hasn't released any market-sensitive news of late, however, anticipated demand in lithium-ion batteries seems to be the catalyst. Furthermore, the spot price for lithium carbonate has roared to 153,000 Chinese yuan per metric tonne (roughly A$32,700).
Novonix was also added to the ASX 300 Index on Monday. This means that fund managers are able to invest in the company.
AGL Energy Limited (ASX: AGL)
The AGL share price is also pushing ahead on Thursday, up 6.69% to $6.06.
Australia's largest electricity provider also hasn't released any new market-sensitive material since the release of its full-year results.
However, analysts at JPMorgan upgraded the company's shares from "Neutral" to "Overweight". Although, the firm cut its price target by 3.2% to $7.55. Based on the current share price, this implies an upside of around 24.5%.
Which ASX companies are heading the other way?
Paladin Energy Ltd (ASX: PDN)
The Paladin share price is down 4% to 84 cents. Investors are selling the company's shares after the spot price of uranium cooled off.
Paladin shares have plunged 18% in a week but are still up more than 500% for the year. In 2021, its shares have risen 240%.
Telix Pharmaceuticals Ltd (ASX: TLX)
Also being weighed down by investors today is the Telix share price, down 3.97% to $6.53.
The biopharmaceutical company provided investors with a United States FDA update for its prostate cancer imaging investigational product, Illuccix. It noted that the approvals process has been extended for a further 3 months.
